These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32339503)

  • 1. Surgically Resected Second Primary Lung Adenocarcinoma After Pembrolizumab Administration.
    Takamori S; Matsubara T; Haratake N; Miura N; Yamaguchi M; Toyozawa R; Seto T; Taguchi K; Takenoyama M
    Ann Thorac Surg; 2020 Nov; 110(5):e377-e379. PubMed ID: 32339503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Let us not underestimate the long-term risk of SPLC after surgical resection of NSCLC.
    Leroy T; Monnet E; Guerzider S; Jacoulet P; De Bari B; Falcoz PE; Gainet-Brun M; Lahourcade J; Alfreijat F; Almotlak H; Adotevi O; Pernet D; Polio JC; Desmarets M; Woronoff AS; Westeel V
    Lung Cancer; 2019 Nov; 137():23-30. PubMed ID: 31521979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
    World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of resected metachronous second non-small cell lung cancer.
    Hamaji M; Ali SO; Burt BM
    Ann Thorac Surg; 2015 Apr; 99(4):1470-8. PubMed ID: 25725930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of severe colitis induced by the administration of pembrolizumab for pulmonary adenocarcinoma in a patient with ulcerative colitis].
    Nishimoto N; Sakakibara Y; Ishida H; Ishihara A; Tanaka S; Hasegawa H; Yamamoto S; Nakazuru S; Mori K; Mita E
    Nihon Shokakibyo Gakkai Zasshi; 2021; 118(12):1122-1129. PubMed ID: 34897141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
    Levy BP; Giaccone G; Besse B; Felip E; Garassino MC; Domine Gomez M; Garrido P; Piperdi B; Ponce-Aix S; Menezes D; MacBeth KJ; Risueño A; Slepetis R; Wu X; Fandi A; Paz-Ares L
    Eur J Cancer; 2019 Feb; 108():120-128. PubMed ID: 30654297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
    Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
    J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A Case in Which Toxic Epidermal Necrosis Developed during Treatment with the Immune Checkpoint Inhibitor Pembrolizumab for Recurrent Patients Following Lung Cancer Surgery].
    Tsujita T; Takahashi S; Oinuma T; Hata N
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1641-1644. PubMed ID: 30449854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.
    Rakaee M; Kilvaer TK; Dalen SM; Richardsen E; Paulsen EE; Hald SM; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Busund LT
    Hum Pathol; 2018 Sep; 79():188-198. PubMed ID: 29885403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary Resection for Second Lung Cancer After Pneumonectomy: A Population-Based Study.
    Ayub A; Rehmani SS; Al-Ayoubi AM; Raad W; Flores RM; Bhora FY
    Ann Thorac Surg; 2017 Oct; 104(4):1131-1137. PubMed ID: 28709663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
    Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
    Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
    Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
    Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis.
    Osa A; Uenami T; Naito Y; Hirata H; Koyama S; Takimoto T; Shiroyama T; Futami S; Nakatsubo S; Sawa N; Yano Y; Nagatomo I; Takeda Y; Mori M; Kida H; Kumanogoh A
    Thorac Cancer; 2019 Nov; 10(11):2183-2187. PubMed ID: 31520515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
    BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab-induced vitiligo in a patient with lung adenocarcinoma: A case report.
    Bulat V; Likic R; Bradic L; Speeckaert R; Azdajic MD
    Br J Clin Pharmacol; 2021 Jun; 87(6):2614-2618. PubMed ID: 33217043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer.
    Fujita T; Hayama N; Kuroki T; Shiraishi Y; Amano H; Nakamura M; Hirano S; Aramaki N; Ichinose S; Shimizu S; Tabeta H; Nakamura S
    Thorac Cancer; 2019 Nov; 10(11):2179-2182. PubMed ID: 31512401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.